This trial will investigate whether semaglutide, a weight-loss drug, is effective in reducing body weight in overweight or obese individuals with schizophrenia-spectrum disorders who are on antipsychotic medications and do not demonstrate adequate weight loss on metformin.
1 Primary · 15 Secondary · Reporting Duration: 32 weeks
92 Total Participants · 2 Treatment Groups
Primary Treatment: Semaglutide · Has Placebo Group · N/A
Age 18 - 55 · All Participants · 4 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: